Vertex to Announce Second Quarter 2021 Financial Results
Listen to the webcast on July 29 at 5:30 p.m. EDT
New data for investigational gene editing program presented at EHA
Vertex and CRISPR Therapeutics share new clinical data on investigational potential treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting
U.S. FDA Approves Expanded Indication for Our Fourth Cystic Fibrosis Medicine
View our 2020 Corporate Responsibility Report
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2020.
Featured contents
We Are Vertex